The Parkinson’s Foundation alerts the community that the US Food and Drug Administration (FDA) has approved safinamide tablets (Xadago®) as an add-on treatment for people with Parkinson’s who are currently taking carbidopa/levodopa and experiencing “off” episodes. The FDA announced the approval on March 21.
Carbidopa/levodopa is the gold-standard therapy for Parkinson’s movement symptoms. As Parkinson’s progresses, many people experience “off” periods in which the drug wears off and movement symptoms return before the next dose. "Off" periods can be very disabling.